DeepMed Research

Cytokinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 564

Market Cap: $6.5B

Website

Clinical Trials

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Phase 2

Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Drug: 25 mg Omecamtiv Mecarbil
Drug: Placebo
Drug: 37.5 mg Omecamtiv Mecarbil
Drug: 50 mg Omecamtiv Mecarbil

First Posted Date: 2016-03-01

Last Posted Date: 2021-07-27

Lead Sponsor: Cytokinetics

Target Recruit Count: 81

Registration Number: NCT02695420

Locations: 🇯🇵
Research Site, Shinagawa-ku, Tokyo, Japan

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Phase 2

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Reldesemtiv 150 mg
Drug: Reldesemtiv 450 mg
Drug: Placebo

First Posted Date: 2016-01-01

Last Posted Date: 2020-08-31

Lead Sponsor: Cytokinetics

Target Recruit Count: 70

Registration Number: NCT02644668

Locations: 🇺🇸
Pediatric Neuromuscular Clinic Stanford University, Palo Alto, California, United States
🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Hospital for Special Care, New Britain, Connecticut, United States

and more 16 locations

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Omecamtiv mecarbil
Drug: Placebo

First Posted Date: 2015-11-10

Last Posted Date: 2021-07-27

Lead Sponsor: Cytokinetics

Target Recruit Count: 50

Registration Number: NCT02601001

Locations: 🇯🇵
Research Site, Kagoshima-shi, Kagoshima, Japan

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo tablets
Drug: Tirasemtiv

First Posted Date: 2015-07-14

Last Posted Date: 2020-09-09

Lead Sponsor: Cytokinetics

Target Recruit Count: 744

Registration Number: NCT02496767

Locations: 🇺🇸
West Virginia University Department of Neurology, Morgantown, West Virginia, United States
🇨🇦
CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus, Quebec, Canada
🇺🇸
Georgia Regents University, Augusta, Georgia, United States

and more 78 locations

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Phase 2

Completed

Conditions: Echocardiogram
Left Ventricular Systolic Dysfunction
Chronic Heart Failure
Left Ventricular Ejection Fraction
Modified Release Oral Formulation
History of Chronic Heart Failure
Pharmacokinetics

Interventions: Drug: Omecamtiv Mecarbil Swellable Core Technology F2
Drug: Placebo
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Drug: Omecamtiv Mecarbil Matrix F2 Formulation

First Posted Date: 2013-02-08

Last Posted Date: 2021-08-12

Lead Sponsor: Cytokinetics

Target Recruit Count: 544

Registration Number: NCT01786512

Locations: 🇬🇧
Research Site, London, United Kingdom

Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: AMG 423

First Posted Date: 2012-11-30

Last Posted Date: 2021-07-30

Lead Sponsor: Cytokinetics

Target Recruit Count: 13

Registration Number: NCT01737866

Locations: 🇺🇸
Research Site, Orlando, Florida, United States

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Other: Placebo tablets
Drug: CK-2017357
Drug: Riluzole

First Posted Date: 2012-10-18

Last Posted Date: 2020-03-31

Lead Sponsor: Cytokinetics

Target Recruit Count: 711

Registration Number: NCT01709149

Locations: 🇺🇸
Texas Neurology, Dallas, Texas, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Drexel Neurology, Philadelphia, Pennsylvania, United States

and more 72 locations

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: CK-2017357
Drug: Riluzole 50 MG

First Posted Date: 2011-12-07

Last Posted Date: 2019-05-03

Lead Sponsor: Cytokinetics

Target Recruit Count: 27

Registration Number: NCT01486849

Locations: 🇺🇸
University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States
🇺🇸
Coordinated Clinical Research, La Jolla, California, United States
🇺🇸
Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States

and more 8 locations

A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: placebo
Drug: omecamtiv mecarbil

First Posted Date: 2011-06-27

Last Posted Date: 2015-10-14

Lead Sponsor: Cytokinetics

Target Recruit Count: 35

Registration Number: NCT01380223

Locations: 🇬🇧
ICON Development Solutions, Manchester, England, United Kingdom

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo (Part A)
Drug: Riluzole 50 MG (Part B)
Drug: CK-2017357 (Part A)
Drug: Placebo (Part B)
Drug: CK-2017357 (Part B)

First Posted Date: 2011-06-22

Last Posted Date: 2019-05-07

Lead Sponsor: Cytokinetics

Target Recruit Count: 49

Registration Number: NCT01378676

Locations: 🇺🇸
SUNY Upstate Medical Center, Syracuse, New York, United States
🇺🇸
University of Kansas, Kansas City, Kansas, United States
🇺🇸
Mayo Florida, Jacksonville, Florida, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy